Compare NSRX & GSIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NSRX | GSIW |
|---|---|---|
| Founded | 2019 | 2016 |
| Country | Israel | Hong Kong |
| Employees | 7 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.2M | 33.5M |
| IPO Year | N/A | 2022 |
| Metric | NSRX | GSIW |
|---|---|---|
| Price | $3.20 | $30.50 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $19.67 | N/A |
| AVG Volume (30 Days) | ★ 52.6K | 2.2K |
| Earning Date | 03-25-2026 | 08-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.98 | $0.05 |
| 52 Week High | $9.99 | $36.90 |
| Indicator | NSRX | GSIW |
|---|---|---|
| Relative Strength Index (RSI) | 54.73 | 65.39 |
| Support Level | $2.04 | $0.11 |
| Resistance Level | $3.48 | $32.25 |
| Average True Range (ATR) | 0.25 | 1.98 |
| MACD | 0.02 | -0.42 |
| Stochastic Oscillator | 63.64 | 76.56 |
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong; and I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.